181 related articles for article (PubMed ID: 34028984)
1. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational study.
Cai B; Fulcher N; Boyd M; Spira A
Thorac Cancer; 2021 Jul; 12(14):2055-2064. PubMed ID: 34028984
[TBL] [Abstract][Full Text] [Related]
2. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
[TBL] [Abstract][Full Text] [Related]
3. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
Wang W; Men Y; Wang J; Zhou Z; Chen D; Xiao Z; Feng Q; Lv J; Liang J; Bi N; Gao S; Wang L; Hui Z
BMC Cancer; 2019 May; 19(1):478. PubMed ID: 31113432
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
6. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
7. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
8. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
9. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.
Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
Interact Cardiovasc Thorac Surg; 2013 Feb; 16(2):166-72. PubMed ID: 23143203
[TBL] [Abstract][Full Text] [Related]
10. Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: A retrospective observational study.
Shah A; Apple J; Belli AJ; Barcellos A; Hansen E; Fernandes LL; Zettler CM; Wang CK
Cancer Treat Res Commun; 2023; 36():100742. PubMed ID: 37478531
[TBL] [Abstract][Full Text] [Related]
11. [Neoadjuvant Radiochemotherapy Followed by Curative Resection in Patients with Advanced Non-Small Cell Lung Cancer in Stage IIIA/IIIB: Prognostic Factors and Results].
Schreiner W; Dudek W; Lettmaier S; Gavrychenkova S; Rieker R; Fietkau R; Sirbu H
Zentralbl Chir; 2016 Jun; 141(3):323-9. PubMed ID: 27035568
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
Tsuchiya T; Matsumoto K; Miyazaki T; Doi R; Tokunaga S; Yamaguchi H; Tomoshige K; Watanabe H; Nagayasu T; Sugio K
BMC Cancer; 2021 Mar; 21(1):249. PubMed ID: 33685421
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer.
Shimada Y; Suzuki K; Okada M; Nakayama H; Ito H; Mitsudomi T; Saji H; Takamochi K; Kudo Y; Hattori A; Mimae T; Aokage K; Nishii T; Tsuboi M; Ikeda N
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):895-901. PubMed ID: 27543652
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).
Lee SW; Choi EK; Chung WK; Shin KH; Ahn SD; Kim JH; Kim SW; Suh C; Lee JS; Kim WS; Kim DS; Kim DK; Park SI; Sohn KH
Lung Cancer; 2002 Jul; 37(1):65-71. PubMed ID: 12057869
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
[No Abstract] [Full Text] [Related]
17. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.
Shen WY; Ji J; Zuo YS; Pu J; Xu YM; Zong CD; Tao GZ; Chen XF; Ji FZ; Zhou XL; Han JH; Wang CS; Yi JG; Su XL; Zhu WG
Radiother Oncol; 2014 Jan; 110(1):120-5. PubMed ID: 24183868
[TBL] [Abstract][Full Text] [Related]
18. Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer.
Bott MJ; Patel AP; Crabtree TD; Morgensztern D; Robinson CG; Colditz GA; Waqar S; Kreisel D; Krupnicka AS; Patterson GA; Broderick S; Meyers BF; Puri V
Ann Thorac Surg; 2015 Jun; 99(6):1921-8. PubMed ID: 25912748
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences.
Oven Ustaalioglu BB; Unal OU; Turan N; Bilici A; Kaya S; Eren T; Ulas A; Inal A; Berk V; Demirci U; Alici S; Bal O; Benekli M; Gumus M
Asian Pac J Cancer Prev; 2013; 14(11):6287-92. PubMed ID: 24377519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
